While a possible impact of 5-ARIs on the natural history of prostate cancer remains a subject of debate [16,17], a likely explanation of our results is the well-documented decrease in PSA levels caused by 5-ARI therapy [18]. The gene discussed is KLK3; the disease is prostate cancer.